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Chronic ulcers represent a major health problem in diabetic patients resulting in pain and discomfort. Conventional therapy does
not guarantee adequate wound repair. In diabetes, impaired healing is partly due to poor endothelial progenitor cells mobilisation
and homing, with altered levels of the chemokine stromal-derived factor-1 (SDF-1) at the wound site. Adipose tissue-associated
stromal cells (AT-SCs) can provide an accessible source of progenitor cells secreting proangiogenic factors and diﬀerentiating
into endothelial-like cells. We demonstrated that topical administration of AT-SCs genetically modified ex vivo to overexpress
SDF-1, promotes wound healing into diabetic mice. In particular, by in vivo bioluminescent imaging analysis, we monitored
biodistribution and survival after transplantation of luciferase-expressing cells. In conclusion, this study indicates the therapeutic
potential of AT-SCs administration in wound healing, through cell diﬀerentiation, enhanced cellular recruitment at the wound
site, and paracrine eﬀects associated with local growth-factors production.
1. Introduction
Skin ulcers due to micro/macrovascular disease and periph-
eral neuropathy represent a common complication in
diabetes. Patients suﬀering from chronic wounds have a
diminished quality of life, require frequent hospitalization,
and experience increased morbidity and mortality, causing
great societal and economical costs [1]. Current treatments,
which include relief of pressure at the wound site, aggressive
surgical debridement, control of infection, and arterial
reconstruction, are limited in eﬀectiveness and often not suf-
ficient to guarantee adequate healing [2]. In fact, a significant
number of patients do not respond to conventional therapies,
and recurrence of symptoms is frequent. Short protein half-
life and ineﬃcient delivery to target cells hamper some
nonconventional treatments, including topical application of
recombinant growth factors to promote tissue regeneration
[3].
Given the increased incidence of the disease, it is
necessary to develop improved therapies to treat diabetic
ulcers to reduce patient discomfort and lower societal
burden. Recently, stem cell application has been suggested
as a possible novel therapeutic option to promote chronic
wound healing [4]. In particular, mesenchymal stem cells
isolated from fetal liver [5] and bone marrow [6, 7] can
enhance wound repair through diﬀerentiation and angio-
genesis promotion. Mesenchymal cells sharing similar char-
acteristics of the ones isolated from bone marrow also can
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be derived from adipose tissue [8]. Adipose tissue-derived
stromal cells (AT-SCs), also known as stromal vascular
fraction cells (AT-SVFs), are collected from adipose tissue
by collagenase digestion and diﬀerential centrifugation [9].
Since liposuction involves only local anaesthesia, cells may be
obtained from the patient with a repeatable, nondebilitating
operation and autologously transplanted at the site of tissue
regeneration. The procedure can be performed in a large-
scale, reproducible manner according to GMP regulations,
allowing AT-SCs to be used in preclinical studies and
experimental clinical trials [10].
Adipose tissue-derived multipotential precursor cells are
able to diﬀerentiate in several cells types of both meso-
dermal and nonmesodermal origins, including adipocytes,
chondrocytes, osteocytes, myocytes, hepatocytes, endocrine
pancreatic cells, neurons, and endothelial cells (for review see
[9]).
AT-SCs secrete angiogenic molecules, including HGF,
VEGF, PlGF, IGF, and KGF [11, 12]. Moreover, transcrip-
tional profiling has demonstrated the expression of proan-
giogenic genes [13]. Transplantation of AT-SCs has been
shown to promote therapeutic angiogenesis in hind limb
ischemia in mice [14–16]. This may be due to integration
of AT-SCs into vessels in vivo [17] and to the contribution
to neovascularisation mediated by a paracrine eﬀect [18].
Moreover, AT-SCs can promote human dermal fibroblast
proliferation [12] and wound healing in a mouse model
[19, 20] both via direct cell-to-cell contact and by a paracrine
eﬀect. In addition, a protective eﬀect of AT-SCs and their
secretory factors during oxidative injury has been described
[21]. Improved wound healing of adipose tissue extracts was
determined in a porcine experimental model [6], while AT-
SCs extract did not aﬀect murine wound repair [19].
Taken together, these studies support the development
of approaches using AT-SCs administration to promote
wound healing. Nonetheless, we know very little about how
transplanted cells behave in vivo, as well as their ability of
engraftment, persistence, diﬀerentiation, and biodistribution
after in vivo administration. In vivo studies in animal models
have the potential to demonstrate the clinical potential of
stem cell therapy by elucidating cell biology and physiology
of the transplanted cells and their progeny. Current methods
of studying stem cell fate after administration mainly rely on
histochemical evaluation of samples obtained from sacrificed
animals. This approach is time consuming, laborious, and
expensive, requiring sectioning analysis of multiple samples
deriving from a large number of experimental animals. To
better understand stem cell activity in vivo, rapid, aﬀordable,
and noninvasive imaging techniques are needed.
In order to evaluate engraftment of AT-SCs in a
murine model of diabetic impaired wound healing, we
used bioluminescent imaging to track transplanted cells.
Furthermore, we were interested in determining whether
concomitant overexpression of SDF-1 may further promote
wound healing and cell engraftment. In fact, in the diabetic
condition, impaired healing is at least in part due to SDF-
1 downregulation [22], which aﬀects migration and homing
at the wound site of circulating endothelial progenitor cells
(EPCs) [23]. On the other hand, exogenous administration
at the lesion site of recombinant SDF-1 [24] or of a lentiviral
vector expressing SDF-1 [25] reversed the impaired EPC
homing in a murine model of diabetic wound healing.
Conversely, SDF-1 inhibition in diabetic animals resulted in
further impairment of wound repair [26]. Moreover, SDF-
1 overexpression increased survival and growth of CXCR4-
expressing mesenchymal stem cells both in vitro [27] and in
vivo [28, 29].
Here, we show that topical administration of AT-SCs
promotes wound healing in diabetic mice and determine by
BLI the biodistribution and the kinetic of engraftment of
administered cells.
2. Material and Methods
2.1. Experimental Animals. Mice used in the study were
6- to 8-week-old wild-type Swiss CD1 males, transgenic
mice expressing ubiquitously GFP [30], or GFP and firefly
luciferase [31] from colonies maintained in our institutional
animal facility. All experimental procedures were performed
according to the guidelines of the Italian National Institutes
of Health and were approved by the Institutional Animal
Care and Use Committee.
Induction of diabetes was obtained by intraperitoneal
injection of 50 mg/kg streptozotocin (Sigma-Aldrich, St.
Louis, MO) in 0.05 M Na citrate, pH 4.5, for 5 consecutive
days. Two weeks after the last streptozotocin injection,
animals were fasted for 2 hours and blood glucose level
measured using an Ascensia Confirm glucometer (Bayern
HealthCare, Basel, Switzerland). Mice with glycaemia above
200 mg/dl were selected for further studies. Three weeks later,
diabetic animals were used for wound-healing experiments.
2.2. Cells Isolation. AT-SCs were obtained from 6-week-
old mice as previously described [32]. Briefly, inguinal
subcutaneous fat pads were digested for 45 minutes in a
shaking water bath at 37◦C in PBS containing 2% BSA
and 2 mg/ml collagenase A (Roche Diagnostics, Mannheim,
Germany). After tissue disaggregation, cells were filtered
through a 40 μm cell strainer (BD Falcon, Franklin Lakes,
NJ) and collected by centrifugation at low speed (500 g) to
remove floating mature adipocytes. Cells were then washed
in PBS, counted, and used for wound healing experiments.
With this procedure, we isolated approximately 0.8–1.2× 106
cells from each 6-week-old mouse.
To obtain adipose-derived adherent stromal (ADAS)
[13], sometimes referred to also as adipose issue-derived
mesenchymal cells (AT-MSCs) [33], cells were plated in
DMEM 20% FCS in tissue culture dishes. After an overnight
incubation, the adherent cell population was obtained.
Skin fibroblasts were obtained from the same animals as
previously described [34]. Briefly, skin samples were washed
in PBS, then the subcutaneous tissues were eliminated and
the epidermis removed by enzymatic digestion. After a wash
in PBS, dermal samples were cut into small pieces and treated
with 0.3% trypsin in PBS for 30 min in a 37◦C water bath.
Ice-cold complete medium (DMEM 10% FCS) was then
added and the samples vigorously mixed on a vortex. The
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suspension was passed through a 40 μm cell strainer, and cells
were collected by centrifugation (10 min at 150 × g, 4◦C).
Cells were then washed in PBS and counted and either used
as control for angiogenesis plug assay (see below) or plated
on tissue culture dishes (0.4 × 105 cells/cm2) in complete
medium.
2.3. Construction of Viral Vectors. Recombinant first-
generation E1-E3-deleted adenoviral (Ad) vectors for
expression of SDF-1 and GFP were obtained using the Ad-
Easy system as previously described [35]. After amplification,
the adenoviral vectors were purified by CsCl2 gradient
ultracentrifugation [36] and dialyzed against a solution
containing 3% sucrose, 10 mM Tris, pH 7.8, 150 mM NaCl,
and 10 mM MgCl2. Viral titers were estimated by serial
dilution of the viral stocks in 293 cells and expressed as
plaque-forming units per ml (PFU/ml). Viral stocks were
tested for absence of replication-competent adenovirus on
A549 cells.
2.4. In Vitro Lesion Repair Assay. The assay was performed
as described by Bilic et al. [37] in triplicate. Second passage
mesenchymal cells derived from adipose tissue were grown
to confluence in complete medium (DMEM 20% FCS). Cells
were then transduced by adenoviral-mediated gene transfer
for 1 hour at 37◦C at multiplicity of infection of 10. Cells
were washed with PBS then grown with serum-free medium
supplemented with 0.1% bovine serum albumin (BSA). The
day after gene transfer cell monolayer was lesioned using a
2 mm cell scraper without damaging the dish surface. Lesion
areas were recorded with a digital camera at time zero and
after 1 and 2 days. Analysis was performed by tracing the
lesion edges and calculating the pixel area using the Image
Analysis System (IAS, Delta Sistemi, Rome, Italy). In vitro
lesion repair is expressed as percent of the value calculated
at time zero.
2.5. In Vivo Angiogenesis Gel Plug Assay. The assay is based
on the implant of Matrigel plugs [38]. Freshly isolated AT-
SCs resuspended in PBS were mixed with Cultrex growth
factor-reduced basement membrane extract (Trevigen Inc.,
Gaithersburgh, MD) maintained at 4◦C (liquid state). An
aliquot of 400 μl of Cultrex containing 7 × 105 cells was
injected subcutaneously into Swiss CD1 mice gathered in
experimental groups of 5 animals each near the abdominal
midline. The solution and the syringe were kept on ice
before the injection to prevent gelling in the needle. A
week later, mice were sacrificed and gel plugs removed.
Samples were fixed in 4% formaldehyde and embedded in
paraﬃn for sectioning and histological analysis. Sections
were then processed with Masson Trichromic stain and
capillary density determined.
2.6. Cell Administration at the Wound Site. Hyperglycaemic
animals were sedated by intraperitoneal administration of
Avertin (200 mg/kg, Sigma-Aldrich) and shaved on the
dorsum, and a full-thickness wound was performed on
the dorsal midline using a 3.5 mm-diameter biopsy punch
(Stiefel, Oﬀenbach am Main, Germany). Right after wound
induction, freshly isolated AT-SCs were then administered
site in a single dose (7.5 × 105 cells/mouse dissolved in 40 μl
of saline solution) topically at the lesion. Control animals
received the same volume of saline solution. Wounded
animals were then housed individually.
2.7. Wound Analysis. At diﬀerent time points (0, 3, 5, 7, 10,
and 14 days) after wounding, lesion closure was documented
using a digital camera. Images were processed and analyzed
by tracing the wound margin and calculating the pixel area
using the Image Analysis System (IAS). Re-epithelialisation
is reported as the percentage of the initial wound area and
calculated as re-epithelialisation percentage = [1 − (area
on day of analysis/area on day 0)] × 100 [39]. The day in
which the full-thickness wound was seen to be completely
closed was taken as the day of complete healing. Moreover,
images of haematoxylin and eosin stained slides of each
wound obtained from maximal cross-sections were digitally
acquired, then the epithelial gap (distance between the two
epithelial edges) was measured to assess re-epithelialization.
2.8. Ex Vivo and In Vivo Optical Bioluminescent Imaging.
Ex vivo and in vivo imaging analysis was performed using
the IVIS Lumina from Caliper Life Sciences (Caliper Life
Sciences, Hopkinton, MA). For ex vivo imaging, AT-SCs
isolated from inguinal fad pads from luciferase-expressing
mice were plated into clear bottom tissue culture dishes
and incubated in a solution of D-luciferin (Caliper Life
Sciences) dissolved in prewarmed tissue culture medium
(150 μg/ml) before analysis. For in vivo analysis, mice were
anesthetized with Avertin and D-luciferin dissolved in PBS
(150 mg/kg body weight), was administered i.p. 10 minutes
before analysis. Photons emitted from luciferase-expressing
AT-SCs transplanted into the animals were collected with
final accumulation times of 1 to 5 minutes, depending on the
intensity of the bioluminescence emission. The same mice
were analyzed at diﬀerent time points after transplantation
with the same procedure, providing longitudinal data of
transplanted cells biodistribution and survival.
2.9. Histological Analysis. Biopsies were fixed in 4%
formaldehyde for 48 hours, embedded in paraﬃn,
and serially sectioned (7 μm) perpendicularly to the
wound surface. Every eighth section of each wound was
haematoxylin and eosin stained to perform morphologic
analyses. Immunohistochemistry on formalin fixed,
paraﬃn-embedded tissue was performed with antibodies
against GFP (Abcam Ltd., Cambridge, UK),
2.10. Statistical Analysis. Results are expressed as means ±
SEM. Data analysis and comparisons between control and
treated groups were done with INSTAT (GraphPad, San
Diego). The significance of diﬀerences was assessed with
a two-tailed Student t-test for unpaired data; statistical
significance level was set at P < .05.
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Figure 1: In vitro lesion repair assay. Lesion closure (expressed as % of the area at day 0) in an in vitro lesion repair assay. Nontransduced
AT-SCs (NT) or transduced with an adenoviral vector expressing GFP (Ad-GFP) or expressing SDF-1 and GFP (Ad-SDF-1) were maintained
in serum-free medium supplemented by 0.1% BSA. Control cells were grown in complete medium (DMEM-20% FCS). Data are expressed
as mean ± SEM, and experiment was performed in triplicate. Statistical significance level was set at P < .05. No statistically significant
diﬀerence was assessed between the NT and Ad-GFP-transduced groups. At 48 hours, lesion repair in the Ad-SDF-1 group was improved in
comparison with both NT group (P = .018) and Ad-GFP (∗P = .006). Representative fluorescence micrographs of lesion area (dotted
lines) at day 2. Original magnification 40X.
3. Results and Discussion
3.1. SDF-1 Overexpression Promotes Lesion Repair in AT-
SCs Monolayer Cultures In Vitro. We determine that AT-
SCs have a repair potential in an in vitro lesion repair assay
performed as previously described [37]. AT-SCs cultured
in 20% FCS containing filled a 2 mm gap performed on
the cell monolayer in less than 3 days. Non-transduced
and mock-transduced AT-SCs maintained in serum-free
medium were not able to repair the scratch. Non-transduced
cells performed better than mock-transduced (Ad-GFP),
possibly for toxicity associated with viral exposure, but the
diﬀerence was not statistically significant at 48 hours after
lesion induction. On the other hand, cells after adenoviral-
mediated gene transfer of SDF-1 had an improved lesion
repair potential after 48 hours from the lesion, compared
both with non-transduced and mock-transduced AT-SCs
(Figure 1).
AT-SCs have been shown to express the CXCR4 alpha-
chemokine receptor specific for stromal-derived factor-1,
and its overexpression increases AT-SCs migration and
proliferation [40]. Accordingly, these results indicate that
SDF-1 may act as an autocrine factor on AT-SCs after a viral-
mediated gene transfer that promotes cell proliferation and
migration.
3.2. AT-SCs Promotes In Vivo Angiogenesis in a Gel Plug
Assay. We found that the stromal fraction isolated from
adipose tissue contained a population of cells capable of
diﬀerentiating into endothelial-like structures in a Matrigel
plug assay [14]. To perform this assay, we isolated AT-SCs
from transgenic mice ubiquitously expressing GFP [30] and
then transplanted the plugs containing the GFP-positive
cells in GFP-negative animals. We were then able to detect
endothelial-like structures derived from implanted GFP-
positive AT-SCs (Figure 2(b)), while we failed to detect
similar structure in control mice (Figure 2(a)). In this exper-
imental condition, more than 99% of endothelial-like struc-
tures were derived from GFP-positive cells (Figure 2(d)).
We also performed the assay using AT-SCs transduced
with an adenoviral mock vector and AT-SCs transduced
with an adenoviral vector expressing SDF-1. We observed
that even in normoglycemic conditions, the number of
endothelial-like structures formation was slightly improved
(5%) by SDF-1 overexpression (Figure 2(h)); albeit in the
experimental setting used to perform the analysis (n = 5
per group), the diﬀerence versus the control group did not
achieve statistical significance (P-value ≥ .05).
Matrigel plugs containing an equal number of skin
fibroblasts obtained from the same animals used for isolation
of AT-SCs were used as controls and failed to organize into
endothelial-like structures (data not shown).
In addition, we also performed a Matrigel plug assay
using a conditioned medium obtained from an overnight
culture of AT-SCs and found that secreted soluble fac-
tors produced by AT-SCs may promote angiogenesis
(Figure 2(f)). This is in accordance with several studies
which have proved that AT-SCs secrete a panel of angiogenic
molecules [21], which have the potential to be, at least in
part, responsible for the therapeutic eﬀect we and others have
observed on wound healing.
Collectively these sets of data indicate that AT-SCs are
able to promote vessel formation in vivo in a Matrigel assay
by taking part in vessel-like structure organization and by
secretion of proangiogenic factors.
3.3. AT-SCs Transplantation Promotes Wound Healing in Dia-
betic Animals. For in vivo studies, we used streptozotocin-
induced CD1 diabetic mice receiving a full-thickness wound
on the dorsal midline. We observed that topical adminis-
tration at the lesion site of 7.5 × 105 AT-SCs significantly
enhanced wound healing in diabetic mice (Figure 3).
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Figure 2: In vivo angiogenesis gel plug assay. AT-SCs isolated from ubiquitously GFP-expressing mice were mixed with Cultrex and injected
subcutaneously into CD1 recipient. After 1 week, gel plugs were analyzed and capillary density was determined by Masson Trichromic stain
(b) and anti-GFP immunohistochemistry (d). Control animals received gel plugs containing saline solution (a)–(c). Masson trichromic stain
of implanted gel plugs containing nonconditioned serum-free medium (e) and conditioned medium from AT-SCs cultures (f); AT-SCs were
genetically modified by Ad-GFP (g) and Ad-SDF-1 (h). The number of endothelial-like structures formation was slightly improved by SDF-1
overexpression, but the diﬀerence versus the control group (Ad-GFP) did not achieve statistical significance (P-value ≥ .05).
Mesenchymal cells isolated from adipose tissue represent
a suitable target for cell-mediated gene therapy as they have
been proven to be prone to viral-mediated gene transfer [41].
We then assessed whether overexpression of SDF-1, whose
downmodulation plays a pivotal role in the pathophysiology
of diabetic wounds, might result in a better therapeu-
tic profile of the AT-SCs-mediated treatment. Indeed, we
achieved further improvement by adenoviral-mediated SDF-
1 gene transfer into AT-SCs before topical administration.
Wound area and epithelial gap were significantly reduced
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Figure 3: Wound closure in diabetic animals. Eﬀect of topical
administration of AT-SCs at the lesion site. Four groups of wounded
diabetic mice were treated with saline solution (Saline), AT-SCs not
genetically modified (AT-SCs) or AT-SCs after adenoviral-mediated
gene transfer of GFP (AT-SCs GFP), and SDF-1 (AT-SCs SDF-1).
At diﬀerent time points after wounding, the area of the lesion was
determined using image analysis. Re-epithelialization is reported as
the percentage of the initial wound area (a). Representative images
from an animal from each group were taken immediately after
wounding (day 0) and at diﬀerent time points after injury (b).
Data are expressed as mean ± SEM indicated by error bars; n =
8–12 wounds for each group. Values of the AT-SCs, AT-SCs GFP,
and AT-SCs SDF-1 were significantly diﬀerent (P < .05) when
compared to the saline group at the time points indicated by an
asterisk. Moreover, at 3 and 5 days, wound closure was improved in
AT-SCs SDF-1-treated animals in comparison with the AT-SCs GFP
group (P < .05).
in treated animals. In particular, the percentage of wound
closure 3 days after injury was 24 in control mice 41 and
58%, respectively, in animals receiving AT-SCs and AT-SCs
expressing SDF-1. At 5 days, values were 45, 68, and 78%,
respectively. Full-thickness wounds were completely closed
in 7 to 10 days in all AT-SCs-treated mice, while in controls,
complete healing was achieved later than 14 days after the
punch.
By gross examination and immunohistochemical anal-
ysis, we determined the presence at the site of tissue
regeneration of GFP-positive administered cells several days
after administration (Figure 4). Further studies to determine
biodistribution and persistence of administered cells were
performed using in vivo bioluminescent imaging techniques
(see below).
3.4. Tracking Transplanted AT-SCs by BLI. After in vivo
administration of AT-SCs expressing luciferase, we mon-
itored luciferase expression by real time in vivo imaging
in the whole animal, together with a light photograph, to
provide for anatomical references. The intensity of the signal
detected by in vivo imaging can be precisely quantified
and correlates with the presence of luciferase-expressing
cells, and therefore with eﬀective cell engraftment after
administration. Since luciferin metabolism requires ATP,
only living cells expressing luciferase are able to produce a
signal. The ability to perform repeated analysis on the same
animal at diﬀerent time points allowed us to determine the
kinetic of AT-SCs biodistribution and engraftment at the
wound site.
AT-SCs were isolated from inguinal fad pads from
luciferase-expressing mice. Figure 5 shows the BLI signal
originated from 7.5×105 cells placed on a 96-well cell culture
plate and of the same cells right after topical administration
at the wound site. Quantification of the BLI signal did not
show any statistically significant diﬀerence between non-
transduced cells and AT-SCs transduced with adenoviral
vectors expressing GFP and SDF-1 (Figure 5) at the time of
administration. Diﬀerences in BLI signal observed from cells
placed in a 96 well tissue culture and from the same cells after
administration to the dorsum of the mouse are dependent,
at least in part, on the approximately 3-fold diﬀerence in the
area of a 96-well compared to the area of the biopsy punch.
To determine biodistribution of delivered cells, some
animals were sacrificed 1, 10, and 15 days after wound
induction and topical administration at the lesion site of
AT-SCs expressing luciferase. BLI was performed before and
after sacrifice of the mouse and dissection of the wounded
area. As shown in Figure 6, cells were mainly located at
the lesion site, with minimal spreading from the site of
delivery. Moreover, performing BLI on the dissected tissue
with the skin facing the CCD camera produced a signal that
was consistently lower than the one obtained with flipping
the piece (Figure 6). This reflects the fact that administered
cells mainly contributed to dermal and subdermal tissue
regeneration and engrafted only in small part in the skin.
We detected a positive signal in the region of the skin and
in the corresponding subdermal area even at day 15, when
the wound was entirely healed (Figure 6(c)). This clearly
indicates engraftment and permanence of administered cells
in the regenerated tissue even after complete healing.
The kinetics of engraftment of administered cells,
expressed as percent of the BLI signal at day 0 is reported
on Figure 7, and it inversely correlates with the kinetics of
wound healing as observed in Figure 3. Most of the signal
associated with transplanted cells was lost between day 1
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Figure 4: Analysis of the wound area. Gross examination under fluorescence microscope of wounds 5 days after administration of GFP-
labelled cells. Original magnification 10X (a) and (b) and 40X (c). Anti GFP immunohistochemistry at the lesion site 2 (d) and 5 days post
wounding (e) after administration of GFP labelled AT-SCs. Scale bar D–E 25 μm.
and day 3 after transplantation. A value of approximately
10% of the intensity observed at day 0 was maintained from
day 3 to day 10, indicating cell engraftment. Although at a
lower level, BLI signal was detectable also at 14 days after
cell administration, suggesting cell engraftment at the site of
tissue regeneration.
Dramatic reduction of stem cell survival after adminis-
tration is the main obstacle hampering clinical translation
of cell therapy protocols. In fact, up to 99% of grafted
cells may die within the first few days of transplantation
due to the rigors of the host microenvironment they
are transferred in. This is mainly characterized by short
supply of oxygen or nutritive substrates and by a massive
excess of free radicals [42]. Several strategies to promote
donor cell survival have been evaluated [43]. In particular,
preconditioning of mesenchymal stem cells by treatment
with the recombinant SDF-1 resulted in enhanced survival
and proliferation under anoxic conditions in vitro and in vivo
[44].
The SDF-1α/CXCR4 ligand/receptor axis modulates sev-
eral pivotal biological functions, including increased cell
growth, proliferation, migration, survival, antiapoptosis, and
transcriptional activation. In particular, it has been shown
that overexpression of CXCR4 increases migration and
proliferation of human adipose tissue-derived stromal cells
[40]. As shown in Figure 3, we found that transplantation
of AT-SCs overexpressing SDF-1 promotes wound healing in
diabetic animals. Interestingly, we determined a statistically
significant diﬀerence between BLI signals in animals receiv-
ing AT-SCs expressing SDF-1 relative to controls expressing
GFP, 1 day after administration (Figure 8). This indicates
that SDF-1 overexpression enhances survival/proliferation
of administered cells at the lesion site at this time point,
resulting in beneficial eﬀects. Nonetheless, no statistically
significant diﬀerences between the two groups were observed
at later time points (3, 5, 7, and 14 days), suggesting that
SDF-1 adenoviral-mediated overexpression failed to improve
long-term cell engraftment in our experimental model.
However, SDF-1 overexpression may promote prohealing
eﬀects to dermal fibroblasts and keratinocytes surrounding
the lesion site [12, 21], resulting in improved healing
observed in Figure 3.
Our results show that AT-SCs administration at the lesion
site improves wound healing in diabetic animals within days
from wound induction. BLI imaging data indicate that a
small fraction of administered cells engraft and participate
in repairing the tissue at the lesion site. On the other
hand, the amount of engrafted cells may be too low to
fully explain the mechanisms of tissue regeneration. In
addition, several evidences suggest that AT-SCs may exert
their beneficial eﬀects also via an autocrine eﬀect promoting
self-profileration and via a paracrine eﬀects on dermal
fibroblasts and keratonocytes surrounding the lesion site
[21].
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Figure 5: Ex vivo and in vivo imaging of AT-SCs expressing luciferase at time 0. Freshly isolated AT-SCs from luciferase-expressing mice were
subjected to adenoviral-mediated gene transfer ((a) non-transduced; (b) Ad-mock-transduced; (c) SDF-1-transduced cells). The AT-SCs
were placed in a 96-well cell culture plate and BLI imaging was performed (insert of each figure panel). The same cells were then administered
to hyperglycemic mice right after performing a dorsal lesion and BLI was repeated. Panel (d) shows quantification of the signals. Note. The
diameter of a well of a 96-well plate is 6.4 mm; the diameter of the biopsy punch used to induce wounding is 3.5 mm. Data are expressed as
mean ± SEM indicated by error bars; n = 3 for each group.
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Figure 6: Biodistribution after topical administration at the wound site of AT-SCs expressing luciferase. BLI imaging of representative animals
sacrificed 1 (a), 10 (b), and 15 (c) days after topical administration of luciferase-expressing cells at the wound site (n = 3). The region
surrounding the wound was excided and BLI performed both with the skin facing the CCD camera (a′, b′, and c′) and on the opposite
orientation (a′′, b′′, and c′′). At all time points, cells are mainly located in the lesion area with minimal spreading from the site of topical
administration.
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Figure 7: Persistence and engraftment of AT-SCs expressing luciferase
after topical administration at the wound. Diabetic mice were treated
after wounding with AT-SCs isolated from luciferase-expressing
mice. Longitudinal analysis performed by BLI at diﬀerent time
points after the treatment indicates persistence of signal throughout
the process of wound healing. Representative images from an
experimental animal at diﬀerent time points (n = 6). Data are
indicated as the percentage of the value immediately after topical
administration of the cells (day 0). Values are expressed as mean ±
SEM indicated by error bars.
4. Conclusions
We have demonstrated that topical administration of AT-
SCs improves impaired wound healing in diabetic mice.
Moreover, using BLI, we were able to follow biodistribution
and the kinetics of engraftment, survival, and proliferation of
administered cells, which proved relatively permanent in the
regenerated tissue even after complete healing. In addition,
our data suggest that concomitant genetic manipulation of
transplanted AT-SCs designed to promote overexpression
of SDF-1 may further improve diabetic impaired wound
healing.
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